SHIPPEO
3.6.2024 10:01:28 CEST | Business Wire | Press release
Unipart, a supply chain solutions and performance improvement technologies business, has chosen Shippeo, a global leader in real-time multimodal transportation visibility as its supply chain visibility partner.
Leveraging Shippeo’s unparalleled real-time data and advanced transportation visibility technology, Unipart Logistics enhances its Lead Logistics Partner (LLP) capability to enable customers to better manage suppliers across road, sea, and air logistics, as well as warehousing and in-plant logistics. This empowers them to build resilience and reduce environmental impact across their global supply chain network.
Shippeo aggregates the industry’s largest global dataset, facilitating intelligent routing decisions across various modes of transportation worldwide. Through smarter carrier routing and management, ETA calculation, and in-transit management solutions, Shippeo will provide real-time insights, empowering users of the LLP to bolster supply chain resilience and sustainability, all while prioritising customer-centric operations. LLP users will also gain live insights into inventory, costs, OTIF, and scope 3 CO2 emissions throughout the supply chain, equipping logistics leaders with actionable data to drive informed business decisions. This continuous monitoring offers early alerts for supply chain issues and enables proactive mitigation or avoidance of disruptions.
Welcoming Unipart to Shippeo strengthens our UK presence and aligns with our shared vision for efficient, customer-centric, and sustainable supply chains. Their commitment to innovation and operational excellence perfectly complements Shippeo's real-time visibility platform. We're confident that our platform will empower Unipart to enhance their LLP platform, providing real-time visibility and control to manage their customer's supply chain, boost satisfaction, and achieve their sustainability goals. This partnership underscores our dedication to UK businesses and the increasing demand for real-time transportation visibility solutions," said Stuart Morrison, Shippeo Vice President, Northern Europe.
“Two trusted brands working in partnership delivering the complete end to end supply chain solution is critical to the success of any customer's supply chain. The need for real time visibility matched with the knowledge and expertise of Uniparts LLP offering deliver’s an efficient and sustainable solution. The data that the Shippeo system provides not only benefits the LLP and its customers for operational control, management and supply chain improvements but also supports and focuses all of our efforts on the need for a sustainable future,” said Lee Fox, Sector Strategy and Business Development Director for LLP at Unipart.
You can Shippeo and Unipart at Multimodal UK from June 11-13 in Birmingham. Don't miss the session with Shippeo’s Chief Product Officer, Anand Medepalli, and Unipart’s Director of Business Development and Sector Strategies, Adam Jones, at 10:30 AM GMT on June 11th. They will discuss "Shaping Logistics' Future: Shippeo & Unipart's Real-Time Visibility Story."
About Shippeo
Shippeo is a global leader in real-time multimodal transportation visibility, helping major shippers and logistics service providers operate more resilient, sustainable, and customer-centric supply chains. This is made possible with highly accurate real-time operational visibility and Transport Process Automation™ to streamline transportation processes, reduce latency and improve operational efficiency. Their Multimodal Visibility Network integrates with more than 1,000 TMS, telematics and ELD systems, enabling Shippeo’s platform to provide instant access to real-time shipment tracking across all transport modes, in a single portal, through an intuitive user experience. A proprietary and industry-leading machine learning algorithm offers unmatched ETA accuracy, allowing supply chain companies to quickly anticipate problems, proactively alert customers, efficiently manage exceptions with collaborative workflows, and GHG emissions from supply chain transport. Hundreds of customers, including global brands like Ahold Delhaize, AkzoNobel, Amazon, Avery Dennison, Bosch Siemens Hausgeräte, Carrefour, Coca-Cola HBC, Jaguar Land Rover, Heineken, Kuehne+Nagel, L’Oréal, LVMH, Renault Group, Sabic, Saint-Gobain, Siemens Energy and XPO Logistics, trust Shippeo to track more than 32 million shipments per year across 110 countries. Learn more at www.shippeo.com, LinkedIn, Facebook, X (formerly Twitter)
About Unipart
Unipart Group is a leading provider of supply chain solutions and performance improvement technologies. It has deep expertise and breadth of capabilities in seven core sectors – automotive, rail and public transport, technology, healthcare, aerospace and defence, e-commerce, consumer and retail, and industrial sectors.
Unipart’s customer promise is: ‘To understand the real and perceived needs of our customers better than anyone else and to serve them better than anyone else.’ At the heart of delivering this is ‘The Unipart Way’, which is demonstrated in the way colleagues think, work and behave. The Unipart Way empowers more than 12,000 colleagues across operations in the UK and 20 international markets with a continuous improvement mindset, delivering operational excellence and added value for customers, everyday.
In 2023 Unipart delivered £1bn turnover. In 2024 it is celebrating the 50th Anniversary of the Unipart brand, having been a division within British Leyland in 1974 and becoming a private company through a management buyout in 1987.
Unipart is committed to setting the highest standards for colleague safety and wellbeing and sustainability. In 2023 it became the first organisation ever to be recognised with a world-class safety, wellbeing and sustainability ‘treble’ by the British Safety Council, and had its ambitious near-term and net-zero targets validated by the Science Based Targets initiative (SBTi).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240603664536/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
